Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chinol

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Nuclear Medicine Communications|February 1, 1997
Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targetingM Chinol, G Paganelli, F Sudati, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patientsG Paganelli, S Zoboli, M Cremonesi, et al.
International Journal of Clinical Pharmacology Research|January 1, 1986
Study on the absorption of ketoprofen topically administered in man: comparison between tissue and plasma levelsR Ballerini, A Casini, M Chinol, et al.
Cancer Research|June 5, 2001
111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumorsG Bussolati, M Chinol, B Chini, et al.
Annals of Nuclear Medicine|August 1, 1996
Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritisM Chinol, S Vallabhajosula, S J Goldsmith, et al.
International Journal of Cancer|October 31, 1998
Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23C V Hamby, M Chinol, C J Palestro, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Plasma and synovial fluid concentrations of isoxicam in meniscectomized patientsR Ballerini, A Casini, M Chinol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2001
The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier moleculeM E Perico, M Chinol, A Nacca, et al.
Current Radiopharmaceuticals|June 16, 2012
Yttrium-90 -- current status, expected availability and applications of a high beta energy emitterR Leyva Montaña, I Hernández González, A Alberti Ramirez, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|October 8, 2010
Testing of microbial contamination during the preparation of the radiocompound [⁹⁰Y]DOTATOC for clinical trials: a process validation study by Media Fill approachV Sirna, L Garaboldi, S Papi, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Nuclear Medicine Communications|February 1, 1997
Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targetingM Chinol, G Paganelli, F Sudati, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patientsG Paganelli, S Zoboli, M Cremonesi, et al.
International Journal of Clinical Pharmacology Research|January 1, 1986
Study on the absorption of ketoprofen topically administered in man: comparison between tissue and plasma levelsR Ballerini, A Casini, M Chinol, et al.
Cancer Research|June 5, 2001
111In-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumorsG Bussolati, M Chinol, B Chini, et al.
Annals of Nuclear Medicine|August 1, 1996
Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritisM Chinol, S Vallabhajosula, S J Goldsmith, et al.
International Journal of Cancer|October 31, 1998
Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23C V Hamby, M Chinol, C J Palestro, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Plasma and synovial fluid concentrations of isoxicam in meniscectomized patientsR Ballerini, A Casini, M Chinol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2001
The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier moleculeM E Perico, M Chinol, A Nacca, et al.
Current Radiopharmaceuticals|June 16, 2012
Yttrium-90 -- current status, expected availability and applications of a high beta energy emitterR Leyva Montaña, I Hernández González, A Alberti Ramirez, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|October 8, 2010
Testing of microbial contamination during the preparation of the radiocompound [⁹⁰Y]DOTATOC for clinical trials: a process validation study by Media Fill approachV Sirna, L Garaboldi, S Papi, et al.
Pageof 5